7.03
3.53%
0.24
Dopo l'orario di chiusura:
7.00
-0.03
-0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$6.79
Aprire:
$6.76
Volume 24 ore:
1.67M
Relative Volume:
0.78
Capitalizzazione di mercato:
$499.63M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-4.3129
EPS:
-1.63
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-4.48%
1M Prestazione:
+12.84%
6M Prestazione:
-3.70%
1 anno Prestazione:
+156.57%
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
2024-01-24 | Iniziato | Goldman | Neutral |
2023-03-22 | Downgrade | Goldman | Buy → Neutral |
2022-12-01 | Iniziato | Goldman | Buy |
2021-12-29 | Ripresa | Jefferies | Buy |
2021-06-02 | Iniziato | H.C. Wainwright | Buy |
2021-02-11 | Iniziato | Guggenheim | Buy |
2020-12-14 | Iniziato | Jefferies | Buy |
2020-11-12 | Reiterato | B. Riley Securities | Buy |
2020-09-25 | Iniziato | B. Riley FBR | Buy |
2020-08-14 | Iniziato | Evercore ISI | Outperform |
2020-07-31 | Iniziato | Piper Sandler | Overweight |
2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
2020-02-24 | Ripresa | ROTH Capital | Buy |
2019-07-19 | Iniziato | ROTH Capital | Buy |
2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan
Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com
Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews
Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat
Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN
Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha
When (ALT) Moves Investors should Listen - Stock Traders Daily
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com
Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat
SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance
Altimmune, Inc. (ALT): A Bull Case Theory - MSN
Exchange Traded Concepts LLC Has $1.33 Million Position in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Millennium Management LLC Increases Stake in Altimmune Inc - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading Up 10.7%Should You Buy? - MarketBeat
Learn to Evaluate (ALT) using the Charts - Stock Traders Daily
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - The Manila Times
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Where are the Opportunities in (ALT) - Stock Traders Daily
Consider Buying Potential Takeover Target Altimmune (NASDAQ:ALT) - Seeking Alpha
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - The Manila Times
Altimmune completes enrollment for MASH treatment trial By Investing.com - Investing.com South Africa
Altimmune completes enrollment for MASH treatment trial - Investing.com India
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - The Manila Times
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis - Marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Profund Advisors LLC Sells 94,081 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Wall Street SWOT: Altimmune stock rides wave of promising obesity drug data - Investing.com
Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Altimmune Inc [ALT] Investment Guide: What You Need to Know - Knox Daily
Farallon Capital Management LLC Has $184,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
SEC Form FWP filed by Alta Global Group Limited - Quantisnow
How the (ALT) price action is used to our Advantage - Stock Traders Daily
Unique Fabricating (NYSEAMERICAN:UFAB) Trading Down 17.6% - Defense World
StockWatch: FDA Surprise Lifts Expectations for Applied’s Govorestat - Genetic Engineering & Biotechnology News
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects (NASDAQ:ALT) - Seeking Alpha
Altimmune (NASDAQ:ALT) Trading Up 3.7% - MarketBeat
Milan Fashion Week: At Gucci, making fashion wearable - CNA Luxury
The Best Celebrity Shoes at Gucci’s Spring 2025 Show in Milan: Kirsten Dunst, Lucky Blue Smith, Nara Smith and More - Footwear News
"Commit To It and Do It": Mel and Lyas Gather the Girls for a Gucci SS25 Debrief - Interview
Take a look at celebrities' outfits for Milan Fashion Week's Gucci show - Marca English
Sabato swings into the sixties: What went down at Gucci SS25 - Dazed
TikTok Star Nara Smith Stuns at Gucci’s Spring 2025 Show in Patent Leather Signoria Slingback Pumps at Milan Fashion Week - Yahoo Entertainment
Applied Therapeutics stock surges after FDA update - The Pharma Letter
Altimmune (NASDAQ:ALT) Trading Down 4.5% - MarketBeat
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club - The Motley Fool
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Altimmune Inc Azioni (ALT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):